GSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms in outcomes of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation

Simple item page
dc.contributor.authorPincinato E.C.
dc.contributor.authorCosta E.F.D.
dc.contributor.authorLopes-Aguiar L.
dc.contributor.authorNogueira G.A.S.
dc.contributor.authorLima T.R.P.
dc.contributor.authorVisacri M.B.
dc.contributor.authorCosta A.P.L.
dc.contributor.authorLourenco G.J.
dc.contributor.authorCalonga L.
dc.contributor.authorMariano F.V.
dc.contributor.authorAltemani A.M.A.M.
dc.contributor.authorCoutinho-Camillo C.
dc.contributor.authorChone C.T.
dc.contributor.authorRamos C.D.
dc.contributor.authorAltemani J.M.C.
dc.contributor.authorMoriel P.
dc.contributor.authorLima C.S.P.
dc.date.accessioned2024-03-12T23:51:01Z
dc.date.available2024-03-12T23:51:01Z
dc.date.issued2019
dc.description.abstract© 2019, The Author(s).Cisplatin (CDDP) combined with radiotherapy (RT) is employed in head and neck squamous cell carcinoma (HNSCC) with variable toxicities and clinical response. Glutathione S-transferases (GSTs) participate in CDDP excretion from cells, and genes encoding GSTs, GSTM1, GSTT1and GSTP1, are polymorphic in humans. This prospective study aimed to evaluate the roles of GSTM1, GSTT1, and GSTP1 Ile105Val polymorphisms in outcomes of HNSCC patients treated with CDDP chemoradiation. Ninety patients were genotyped by multiplex PCR. Urinary CDDP measurements were performed by HPLC. Treatment side effects and response were analysed by conventional criteria. Patients with GSTT1 genes showed 7.23- and 5.37-fold higher likelihood of presenting vomiting and ototoxicity, lower glomerular filtration rate (GFR), and lower elimination of CDDP in urine relative to patients with deleted genes. Patients harbouring the GSTP1 IleVal or ValVal genotypes showed 4.28-fold higher likelihood of presenting grade 2 or 3 vomiting and lower GFR with treatment than those harbouring the IleIle genotype. In multivariate Cox analysis, patients with the GSTP1 105ValVal genotype had 3.87 more chance of presenting disease progression than those with the IleIle or IleVal genotype (p < 0.01). Our findings provide preliminary evidence that inherited abnormalities in CDDP metabolism, related to GSTT1 and GSTP1 Ile105Val polymorphisms, alter outcomes of HNSCC patients treated with CDDP and RT.
dc.description.issuenumber1
dc.description.volume9
dc.identifier.doi10.1038/s41598-019-45808-6
dc.identifier.issn2045-2322
dc.identifier.urihttps://dspace.mackenzie.br/handle/10899/35152
dc.relation.ispartofScientific Reports
dc.rightsAcesso Aberto
dc.titleGSTM1, GSTT1 and GSTP1 Ile105Val polymorphisms in outcomes of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation
dc.typeArtigo
local.scopus.citations14
local.scopus.eid2-s2.0-85068052900
local.scopus.subjectAdult
local.scopus.subjectAged
local.scopus.subjectChemoradiotherapy
local.scopus.subjectCisplatin
local.scopus.subjectFemale
local.scopus.subjectGlutathione S-Transferase pi
local.scopus.subjectGlutathione Transferase
local.scopus.subjectHumans
local.scopus.subjectMale
local.scopus.subjectMiddle Aged
local.scopus.subjectPolymorphism, Single Nucleotide
local.scopus.subjectSquamous Cell Carcinoma of Head and Neck
local.scopus.subjectSurvival Analysis
local.scopus.subjectTreatment Outcome
local.scopus.updated2024-05-01
local.scopus.urlhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85068052900&origin=inward
Files
Collections
Artigos de periódico